---
title: "Alithea Genomics launches MERCURIUS™ Total DRUG-seq: a next-generation full-length transcriptome profiling platform for high-throughput compound screening and target validation"
description: Alithea Genomics has announced the launch of MERCURIUS™ Total DRUG-seq, a new extraction-free, full-length transcriptome profiling library preparation kit.
---

[Newsroom](https://news.lifesciencenewswire.com/newsroom)

# [Alithea Genomics launches MERCURIUS™ Total DRUG-seq: a next-generation full-length transcriptome profiling platform for high-throughput compound screening and target validation](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-mercurius-total-drug-seq-a-next-generation-full-length-transcriptome-profiling-platform-for-high-throughput-compound-screening-1750238414592)

 Written by [Life Science Newswire](https://news.lifesciencenewswire.com/newsroom/author/newswire) | Jun 19, 2025 11:00:00 AM

<https://drive.google.com/file/d/1wod15giEhc7e-a3YmsacKKyh9a6J9u0Z/view?usp=drive_link>

[Alithea Genomics](http://alitheagenomics.com), a pioneering biotech company based in Switzerland and the USA specializing in scalable RNA sequencing solutions, today announced the launch of MERCURIUS™ Total DRUG-seq, a new extraction-free, full-length transcriptome profiling library preparation kit designed to push the boundaries of high-throughput drug screens, toxicology screens and target validation by enabling the creation of large-scale data generation for machine learning and AI.

Building on the success of its MERCURIUS™ 3’ DRUG-seq, MERCURIUS™ Total DRUG-seq captures the complete transcriptome—including lncRNAs and other non-coding RNAs—with greater sensitivity, full-length coverage, and unprecedented multiplexing capacity, enabling researchers to screen over 50,000 samples with confidence.

The kit is available in 96-well (1,000–25,000 cells) and 384-well (500–10,000 cells) formats and features a streamlined, extraction-free protocol that delivers faster turnaround, lower input requirements, and expanded insights, without sacrificing scalability or reproducibility.

“MERCURIUS™ Total DRUG-seq represents a new frontier in transcriptome-scale compound screening,” said Riccardo Dainese, CEO and Co-founder of Alithea Genomics. “We are empowering scientists to capture the full complexity of transcriptional responses—at a massive scale and with minimal cost. This product opens the door to discovering new biology, new targets, and new drugs faster than ever before.”

MERCURIUS™ Total DRUG-seq is now available for ordering as a standalone kit or as part of Alithea’s in-house services.

Attendees of Discovery and Development Europe (June 2025) are invited to visit Alithea Genomics at booth 64 to explore the new MERCURIUS™ Total DRUG-seq solution alongside other products in the MERCURIUS™ DRUG-seq product line.

About RNA Sequencing

RNA sequencing (RNA-seq) examines the quantity and sequences of RNA molecules in a biological sample using next-generation sequencing (NGS). By revealing which genes are expressed and to what extent, RNA-seq provides a high-resolution view of cellular function. These insights are essential across the drug discovery pipeline, from biomarker discovery to therapeutic development.

About Alithea Genomics

Alithea Genomics develops innovative, massively multiplexed RNA-seq solutions designed to accelerate high-throughput transcriptomics. Its proprietary MERCURIUS™ DRUG-seq and MERCURIUS™ BRB-seq technologies dramatically reduce the cost and complexity of generating large-scale RNA data, enabling breakthroughs in drug development, crop engineering, cosmetics, and beyond. Founded in 2020 at EPFL in Lausanne, Switzerland, Alithea Genomics operates in Europe and the United States.

[https://alitheagenomics.com](https://alitheagenomics.com) 

[View full post](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-mercurius-total-drug-seq-a-next-generation-full-length-transcriptome-profiling-platform-for-high-throughput-compound-screening-1750238414592)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Life Science Newswire"
  },
  "dateModified" : "2025-06-19T11:00:00.373Z",
  "datePublished" : "2025-06-19T11:00:00Z",
  "headline" : "Alithea Genomics launches MERCURIUS™ Total DRUG-seq: a next-generation full-length transcriptome profiling platform for high-throughput compound screening and target validation",
  "image" : {
    "@type" : "ImageObject",
    "height" : 800,
    "url" : "https://f.hubspotusercontent30.net/hubfs/3338181/LSNewswire-main-header-banner-v2-1.jpg",
    "width" : 1920
  },
  "mainEntityOfPage" : "https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-mercurius-total-drug-seq-a-next-generation-full-length-transcriptome-profiling-platform-for-high-throughput-compound-screening-1750238414592",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Newsroom"
  }
}
```